Haemonetics Total Stockholder Equity vs Short Term Investments Analysis
HAE Stock | USD 84.08 0.57 0.67% |
Haemonetics financial indicator trend analysis is much more than just examining Haemonetics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Haemonetics is a good investment. Please check the relationship between Haemonetics Total Stockholder Equity and its Short Term Investments accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Haemonetics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.
Total Stockholder Equity vs Short Term Investments
Total Stockholder Equity vs Short Term Investments Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Haemonetics Total Stockholder Equity account and Short Term Investments. At this time, the significance of the direction appears to have pay attention.
The correlation between Haemonetics' Total Stockholder Equity and Short Term Investments is -0.85. Overlapping area represents the amount of variation of Total Stockholder Equity that can explain the historical movement of Short Term Investments in the same time period over historical financial statements of Haemonetics, assuming nothing else is changed. The correlation between historical values of Haemonetics' Total Stockholder Equity and Short Term Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Stockholder Equity of Haemonetics are associated (or correlated) with its Short Term Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Term Investments has no effect on the direction of Total Stockholder Equity i.e., Haemonetics' Total Stockholder Equity and Short Term Investments go up and down completely randomly.
Correlation Coefficient | -0.85 |
Relationship Direction | Negative |
Relationship Strength | Significant |
Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Short Term Investments
Short Term Investments is an item under the current assets section of Haemonetics balance sheet. It contains any investments Haemonetics undertook that will expire in less than one year. These accounts contain financial instruments such as stocks or bonds that Haemonetics can easily liquidate in the marketplace.Most indicators from Haemonetics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Haemonetics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Haemonetics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.At present, Haemonetics' Sales General And Administrative To Revenue is projected to slightly decrease based on the last few years of reporting. The current year's Enterprise Value Over EBITDA is expected to grow to 27.05, whereas Selling General Administrative is forecasted to decline to about 234.9 M.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 505.5M | 615.1M | 676.5M | 710.4M | Total Revenue | 993.2M | 1.2B | 1.3B | 1.4B |
Haemonetics fundamental ratios Correlations
Click cells to compare fundamentals
Haemonetics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Haemonetics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Common Stock Shares Outstanding | 51.8M | 51.3M | 51.4M | 51.4M | 51.4M | 42.5M | |
Total Assets | 1.3B | 1.8B | 1.9B | 1.9B | 2.2B | 2.3B | |
Short Long Term Debt Total | 382.5M | 707.6M | 773.6M | 765.9M | 873.9M | 917.6M | |
Other Current Liab | 127.7M | 159.9M | 137.9M | 145.9M | 177.4M | 186.3M | |
Total Current Liabilities | 284.3M | 253.5M | 442.3M | 251.8M | 300.4M | 161.5M | |
Total Stockholder Equity | 587.1M | 731.7M | 749.4M | 818.0M | 960.0M | 535.9M | |
Property Plant And Equipment Net | 253.4M | 217.6M | 258.5M | 310.9M | 366.6M | 185.9M | |
Net Debt | 245.2M | 515.3M | 514.1M | 481.4M | 695.1M | 729.8M | |
Retained Earnings | 78.5M | 158.0M | 202.4M | 253.2M | 360.5M | 281.9M | |
Accounts Payable | 50.7M | 50.3M | 58.4M | 63.9M | 73.4M | 77.0M | |
Cash | 137.3M | 192.3M | 259.5M | 284.5M | 178.8M | 138.4M | |
Non Current Assets Total | 663.5M | 1.1B | 1.1B | 1.2B | 1.4B | 1.5B | |
Non Currrent Assets Other | 66.3M | 76.9M | 63.2M | 107.0M | 88.9M | 99.5M | |
Cash And Short Term Investments | 137.3M | 192.3M | 259.5M | 284.5M | 178.8M | 140.6M | |
Net Receivables | 165.2M | 127.6M | 159.4M | 179.1M | 206.6M | 120.7M | |
Liabilities And Stockholders Equity | 1.3B | 1.8B | 1.9B | 1.9B | 2.2B | 2.3B | |
Non Current Liabilities Total | 395.7M | 834.8M | 668.0M | 865.0M | 935.2M | 982.0M | |
Inventory | 270.3M | 322.6M | 293.0M | 259.4M | 317.2M | 333.1M | |
Other Current Assets | 30.8M | 51.1M | 44.1M | 46.7M | 66.3M | 36.9M | |
Other Stockholder Equity | 553.2M | 602.7M | 572.5M | 594.7M | 634.6M | 666.4M | |
Total Liab | 680.0M | 1.1B | 1.1B | 1.1B | 1.2B | 1.3B | |
Property Plant And Equipment Gross | 305.6M | 217.6M | 869.1M | 944.2M | 959.2M | 1.0B | |
Total Current Assets | 603.6M | 693.5M | 756.0M | 769.7M | 768.9M | 437.2M | |
Accumulated Other Comprehensive Income | (45.1M) | (29.5M) | (26.0M) | (30.4M) | (35.6M) | (37.4M) | |
Short Term Debt | 77.0M | 17.0M | 214.1M | 11.8M | 18.4M | 36.2M | |
Intangible Assets | 133.1M | 365.5M | 310.3M | 275.8M | 406.1M | 426.4M | |
Other Liab | 48.7M | 38.2M | 76.9M | 108.6M | 124.9M | 131.1M | |
Other Assets | 14.1M | 17.0M | 67.7M | 58.8M | 1.0 | 0.95 | |
Long Term Debt | 305.5M | 690.6M | 559.4M | 754.1M | 797.6M | 837.4M | |
Good Will | 210.7M | 466.4M | 467.3M | 466.2M | 565.1M | 593.3M | |
Property Plant Equipment | 253.4M | 277.4M | 258.5M | 310.9M | 357.5M | 213.6M | |
Current Deferred Revenue | 28.8M | 26.3M | 31.8M | 30.2M | 31.2M | 22.5M | |
Net Tangible Assets | 243.4M | (100.3M) | (28.1M) | 76.0M | 68.4M | 65.0M | |
Retained Earnings Total Equity | 78.5M | 158.0M | 202.4M | 253.2M | 227.9M | 230.9M | |
Long Term Debt Total | 305.5M | 690.6M | 559.4M | 754.1M | 867.2M | 910.6M | |
Capital Surpluse | 553.2M | 602.7M | 572.5M | 594.7M | 683.9M | 516.6M | |
Deferred Long Term Liab | 10.6M | 43.8M | 28.7M | 36.2M | 41.6M | 26.4M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Haemonetics is a strong investment it is important to analyze Haemonetics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Haemonetics' future performance. For an informed investment choice regarding Haemonetics Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Haemonetics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.Note that the Haemonetics information on this page should be used as a complementary analysis to other Haemonetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Complementary Tools for Haemonetics Stock analysis
When running Haemonetics' price analysis, check to measure Haemonetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Haemonetics is operating at the current time. Most of Haemonetics' value examination focuses on studying past and present price action to predict the probability of Haemonetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Haemonetics' price. Additionally, you may evaluate how the addition of Haemonetics to your portfolios can decrease your overall portfolio volatility.
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Stocks Directory Find actively traded stocks across global markets | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |
Is Haemonetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Haemonetics. If investors know Haemonetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Haemonetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.30) | Earnings Share 2.29 | Revenue Per Share 25.817 | Quarterly Revenue Growth 0.128 | Return On Assets 0.0626 |
The market value of Haemonetics is measured differently than its book value, which is the value of Haemonetics that is recorded on the company's balance sheet. Investors also form their own opinion of Haemonetics' value that differs from its market value or its book value, called intrinsic value, which is Haemonetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Haemonetics' market value can be influenced by many factors that don't directly affect Haemonetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Haemonetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Haemonetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Haemonetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.